Condition (MeSH)
Fish Diseases
ClinicalTrials.gov lists 14 trials for Fish Diseases or a narrower condition beneath it. AbbVie (prior sponsor, Abbott) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
When did Fish Diseases trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2019 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2013 | 1 |
| 2012 | 1 |
| 2011 | 3 |
| 2010 | 1 |
| 2009 | 1 |
| 2008 | 2 |
| 2007 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 14 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Fish Diseases trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 6 |
| Observational | 1 |
How many Fish Diseases trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 11 |
| Terminated | 2 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Fish Diseases trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AbbVie (prior sponsor, Abbott) | 2 |
| Laboratorios Goulart S.A. | 1 |
Which drugs are being tested for Fish Diseases? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Mupirocin | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 2% Mupirocin Ointment | 2 |
| Adalimumab-US | 2 |
| Vapocoolant | 1 |
| Hydroxychloroquin | 1 |
| 4% Chlorhexidine liquid soap | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Fish Diseases trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| HIDRADENITIS | 14 | 2 |
| ABORTION INDUCED | 2 | 2 |
| ECTOPIC PREGNANCY | 2 | 1 |
| PNEUMONIA | 2 | 2 |
| SUICIDE ATTEMPT | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Fish Diseases? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Novel IFNγ homologue identified in Nile tilapia (Oreochromis niloticus) links with immune response in gills under different stimuli. | Fish & shellfish immunology | 2017 | Yes |
| Integrated profiling of global metabolomic and transcriptomic responses to viral hemorrhagic septicemia virus infection in olive flounder. | Fish & shellfish immunology | 2017 | Yes |
| Isolation and characterization of new potential probiotic bacteria based on quorum-sensing system. | Journal of applied microbiology | 2011 | Yes |
| The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. | Cell | 2010 | Yes |
| Miswak (Salvadora persica) dietary supplementation improves antioxidant status and nonspecific immunity in Nile tilapia (Oreochromis niloticus). | Fish & shellfish immunology | 2019 | No |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.